Genetics

(109) Prenatal diagnostic testing trends in the era of cell-free DNA screening

(143) Accuracy of fetal fraction measurements in SNP-based non-invasive prenatal testing (NIPT)

(169) Curating the fetal genome: Experience of the ClinGen Prenatal Gene Curation Expert Panel (GCEP)

(194) Fetal fraction amplification dramatically increases PPV for 22q11.2 deletion syndrome in prenatal cell-free DNA screening

(208) Next generation sequencing application in congenital fetal anomalies

(234) Expanded carrier screening for genetic conditions with clinical trials in-utero therapy

(250) Preimplantation genetic testing (PGT) for non-homologous Robertsonian translocation carriers: a twelve-year laboratory experience

(334) Is there clinical utility of PAPP-A in the age of cell free DNA?

(354) Invasive Testing for Abnormal NIPT Before and After the Texas Heartbeat Act

(428) Cost-effectiveness of BRCA1 testing at time of obstetrical prenatal carrier screening for cancer prevention

(511) Comparing the yield of meaningful findings in targeted versus genome-wide cell free DNA screening

(563) Cell free DNA whole genome (cfDNA-WG) in clinical practice: a single center 6-year experience

(571) Assessment of provider knowledge and recommendations for spinal muscular atrophy carrier testing

(631) Clinical utility of antenatal cfDNA screening for autosomal dominant disorders in the general population

(647) Patient Cost Willingness for Diagnostic Prenatal Testing in a Region with Poor Insurance Coverage

(677) Unusual presentation of renal tubular dysgenesis: a case report and review of current literature

(727) One laboratory’s experience with prenatal cfDNA screening and incidental findings concerning for maternal neoplasia

(743) Utility of genetic testing in fetuses with suspected lethal skeletal dysplasia on sonography

(766) Obstetric and fetal outcomes with high risk and non-reportable low fetal fraction cell-free DNA results

(800) Variation in genetic workup of polyhydramnios: An international and inter-specialty survey

(819) Trends and outcomes in deliveries affected by maternal fatty acid oxidation defects

(829) Cost-effectiveness of exome and genome sequencing for low-risk pregnancies

(874) How common are fetal genetic abnormalities in “low-risk” patients undergoing genetic testing?

(900) What is the clinical utility and accuracy of single gene NIPT for recessive mendelian disorders?

(906) Patient Weight, Not Height, Significantly Influences cfDNA Screening Performance

(910) Performance of SNP-based cell-free DNA prenatal screening for 22q11.2 deletion syndrome in a commercial population

(989) Maternal and ultrasound characteristics associated with persistence of cell-free DNA from a vanishing twin pregnancy

(1005) The clinical experience of prenatal whole genome sequencing in a maternal fetal medicine practice

(1049) The Association Between Stillbirth and Maternal Serum Analyte Levels

(1127) Prenatally Diagnosed Genetic Anomalies, Anticipated Phenotypes, and Pregnancy Outcomes

(1128) Reliability of FISH by Testing Indication

(1152) Positive Carrier Screening for Alport Syndrome: A Need for Greater Awareness

(1181) Maternal and fetal tissue specific response to phthalate exposure in the third trimester